Clofarabine for the treatment of adult acute lymphoid leukemia: The Group for Research on Adult Acute Lymphoblastic Leukemia intergroup

Leukemia and Lymphoma

Volumn 56, Issue 4, 2015, Pages 847-857

  Huguet, Françoise ^a   Leguay, Thibaut ^b   Raffoux, Emmanuel ^c   Rousselot, Philippe ^d   Vey, Norbert ^e   Pigneux, Arnaud ^b   Ifrah, Norbert ^f   Dombret, Hervé ^c  

^a CHU PURPAN   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d CENTRE HOSPITALIER DE VERSAILLES   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Acute lymphoblastic leukemia; Adults; Clofarabine; Purine analogs

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ASPARAGINASE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; MITOXANTRONE; NAVELBINE; THIOTEPA; TOPOTECAN; ADENINE NUCLEOTIDE; ANTINEOPLASTIC AGENT; ARABINONUCLEOSIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT DISEASE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CAPILLARY LEAK SYNDROME; CELL LINEAGE; CHILDHOOD LEUKEMIA; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY FAILURE; LIVER TOXICITY; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PANCREATITIS; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; RASH; TUBERCULOSIS; VEIN OCCLUSION; ADULT; CHILD; DOSE RESPONSE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; REMISSION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADENINE NUCLEOTIDES; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84929084451     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.887708     Document Type: Article

References (83)

1. Fielding A. The treatment of adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2008:381-389.
2. Ottmann OG, Pfeifer H. Management of Philadelphia chromosomepositive acute lymphoblastic leukemia (Ph + ALL). Hematology Am Soc Hematol Educ Program 2009:371-381.
3. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535-1548.
4. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007;446:758-764.
5. Familiades J, Bousquet M, Lafage-Pochitaloff M, et al. PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia 2009;23:1989-1998.
6. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009;360:470-480.
7. Ben Abdelali R, Asnafi V, Leguay T, et al. Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. Blood 2011;118:5099-5107 .
8. Bedford K, Macintyre E, Lhéritier V, et al . Minimal residual disease at 3 months, combined to the presence of IKZF1 deletion in B-lineage or absence of NOTCH1 pathway mutation in T-lineage, recapitulates the disease risk assessment in adults with Philadelphia chromosomenegative acute lymphoblastic leukemia - a GRAALL Study. Blood 2011;118 (Suppl. 1): Abstract 572.
9. Gokbuget N, Kneba M, Raff T, et al. Adults with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012;120:1868-1876.
10. Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001;15:163-205.
11. Advani A, Jin T, Bolwell B, et al . A prognostic scoring system for adult patients less than 60 years of age with acute lymphoblastic leukemia in first relapse. Leuk Lymphoma 2009;50:1126-1131.
12. Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010;95:589-596.
13. Tavernier E, Boiron JM, Huguet F, et al . Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007;21:1907-1914.
14. Terwey TH, Massenkeil G, Tamm I, et al . Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy. Bone Marrow Transplant 2008;42:791-798.
15. O'Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008;113:3186-3191.
16. Larson RA. Acute lymphoblastic leukemia: older patients and newer drugs. Hematology Am Soc Hematol Educ Program 2005:131-136.
17. Cohen MH, Johnson JR, Justice R, et al. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist 2008;13:709-714.
18. DeAngelo DJ. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma . Hematol Oncol Clin North Am 2009;23:1121-1135, vii-viii.
19. Jeha S. Recent progress in the treatment of acute lymphoblastic leukemia: clofarabine. Hematol Oncol Clin North Am 2009;23:1137-1144, viii.
20. Gandhi V, Kantarjian H, Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 2003;9:6335-6342.
21. Lotfi K, Mansson E, Spasokoukotskaja T, et al. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999;5:2438-2444.
22. Galmarini CM, Popowycz F, Joseph B. Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy. Curr Med Chem 2008;15:1072-1082.
23. Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. Cancer Res 1996;56:3030-3037.
24. Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000;96:3537-3543.
25. Bonate PL, Arthaud L, Cantrell WR Jr, et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006;5:855-863.
26. Styczynski J, Gil L, Derwich K, et al. Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study. Anticancer Res 2009;29:1643-1650.
27. Yamauchi T, Nowak BJ, Keating MJ, et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001;7:3580-3589.
28. Karp JE, Ricklis RM, Balakrishnan K, et al. A phase 1 clinicallaboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007;110:1762-1769.
29. Cooper T, Ayres M, Nowak B, et al. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol 2005;55:361-368.
30. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005;105:940-947.
31. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004;103:784-789.
32. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006;24:1917-1923 .
33. Kearns P, Michel G, Nelken B, et al. A European phase II study (BIOV-111) of clofarabine (Evoltra®) in refractory and relapsed childhood acute lymphoblastic leukemia: final results. Blood 2007;110(Suppl. 1): Abstract 11.
34. Hijiya N, Gaynon P, Barry E, et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 2009;23:2259-2264.
35. Hijiya N, Thomson B, Isakoff MS, et al. Phase II trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory/relapsed acute lymphoblastic leukemia. Blood 2011;118:6043-6049.
36. O'Connor D, Sibson K, Caswell M, et al . Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. Br J Haematol 2011;154:482-485.
37. Locatelli F, Testi AM, Bernardo ME, et al. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol 2009;147:371-378.
38. Miano M, Pistorio A, Putti MC, et al. Clofarabine, cyclophosphamide, and etoposide (CLOVE) treatment followed by SCT for relapsed or resistant acute leukaemia in paediatric patients. Presented at: 37th EBMT Annual Meeting, 3-6 April 2011, Paris, France.
39. Cooper T, Alonzo TA, Gerbing RB, et al. AAML0523: a report from the Children's Oncology Group on the safety of clofarabine in combination with cytarabine in pediatric patients with relapsed acute leukemia. Blood 2009;114 (Suppl.): Abstract 3076.
40. Steinherz PG, Shukla N, Kobos R, et al. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Pediatr Blood Cancer 2010;54:687-693.
41. Thomas X, Raffoux E, Elhamri M, et al. Clofarabine for the treatment of adult acute myeloid leukemia. Future Oncol 2009;5:1197-1210.
42. Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003;21:1167-1173.
43. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638-1645 .
44. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379-2386.
45. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010;28:2389-2395.
46. Faderl S, Ravandi F, Garcia-Manero G, et al. Frontline therapy for older patients (pts) with acute myeloid leukemia (AML): clofarabine plus low-dose cytarabine induction followed by prolonged consolidation with clofarabine plus low-dose cytarabine alternating with decitabine. Blood 2010;116 (Suppl. 1): Abstract 336.
47. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010;28:549-555.
48. Becker PS, Kantarjian HM, Appelbaum FR, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol 2011;155:182-189.
49. Th omas X, Lobe I, Raffoux E, et al. Intensive consolidation with clofarabine and intermediate-dose cytarabine (CLARA) in patients with high-risk AML in first CR: the ALFA-0702 pilot study. Blood 2008;112(Suppl. 1): Abstract 1934.
50. Faderl S, Ferrajoli A, Wierda W, et al. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 2008;113:2090-2096 .
51. Naqvi K, Ravandi F, Kantarjian H, et al. Phase II study of the combination of clofarabine plus idarubicin and cytarabine (CIA) in patients with relapsed/refractory acute myeloid leukemia (AML). Blood 2010;116(Suppl. 1): Abstract 1061.
52. Faderl S, Thomas DA, Gandhi V, et al. Phase I/II study of clofarabine plus cyclophosphamide in adults with relapsed and refractory acute lymphoblastic leukemia (ALL). Blood 2007;110(Suppl. 1): Abstract 4335.
53. Agura E, Cooper B, Holmes H, et al. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist 2011;16:197-206.
54. McGregor BA, Brown AW, Osswald MB, et al. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. Am J Hematol 2009;84:228-230.
55. Miano M, Pistorio A, Putti MC, et al. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. Leuk Lymphoma 2012;53:1693-1698.
56. Dressel A, Kwari M, McGreal AM. Nursing considerations for optimal outpatient management of adult patients with leukemia treated with clofarabine. Clin J Oncol Nurs 2011;15:E13-E23.
57. McDonald LR, McCarthy CH. Nursing considerations for clofarabine in the treatment of acute lymphoblastic leukemia in children. Clin J Oncol Nurs 2006;10:809-815.
58. Genzyme. Clolar ®/Evoltra®. Summary of product characteristics. 2011.
59. Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006;108:45-51.
60. Choi J, Foss F. Efficacy of low dose clofarabine in refractory precursor T-acute lymphoblastic leukemia. Yale J Biol Med 2006;79:169-172.
61. Advani AS, Gundacker HM, Sala-Torra O, et al. Southwest Oncology Group study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol 2010;151:430-434.
62. Papayannidis C, Derenzini E, Iacobucci I, et al. Successful combination treatment of clofarabine, cytarabine, and gemtuzumabozogamicin in adult refractory B-acute lymphoblastic leukemia. Am J Hematol 2009;84:849-850.
63. Chawla B, Kanate AS, Osman S, et al . Clofarabine in combination with cyclophosphamide for treatment of relapsed/refractory acute leukemia in adult patients. Blood 2010;116(Suppl. 1): Abstract 4367.
64. Grigoleit GU, Kapp M, Tan SM, et al. Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series. Leuk Lymphoma 2009;50:2071-2074.
65. Vitale A, Grammatico S, Capria S, et al. Advanced Philadelphia chromosome positive acute lymphoblastic leukemia patients relapsed after treatment with tyrosine-kinase inhibitors: successful response to clofarabine and cyclophosphamide. Haematologica 2009;94:1471-1473.
66. Domenech C, Mercier M, Plouvier E, et al. First isolated extramedullary relapse in children with B-cell precursor acute lymphoblastic leukaemia: results of the Cooprall-97 study. Eur J Cancer 2008;44:2461-2469.
67. Pigneux A, Sauvezie M, Vey N, et al. Clofarabine combinations in adults with refractory/relapsed acute lymphoblastic leukemia (ALL): a GRAALL report. Blood 2011;118(Suppl. 1): Abstract 2586.
68. Fu CH, Sakamoto KM. PEG-asparaginase. Expert Opin Pharmacother 2007;8:1977-1984.
69. Domenech C, Thomas X, Chabaud S, et al. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol 2011;153:58-65.
70. Hunault-Berger M, Leguay T, Thomas X, et al. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study. Haematologica 2011;96:245-252.
71. Heffner L Jr. A new formulation of vincristine for acute lymphoblastic leukemia. Clin Adv Hematol Oncol 2011;9:314-316.
72. Larson RA. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine. Semin Oncol 2007;34:S13-S20.
73. Chevallier P, Robillard N, Charbonnier A, et al. Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. Blood 2012;119:2474-2477 .
74. Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol 2008;26:3756-3762.
75. Topp M, Goekbuget N, Zugmaier G, et al. Anti-CD19 BiTE blinatumomab induces high complete remission rate in adult patients with relapsed B-precursor ALL: updated results of an ongoing phase II trial. Blood 2011;118(Suppl. 1): Abstract 252.
76. Kebriaei P, Wilhelm K, Ravandi F, et al. Inotuzumab ozogamicin (IO) is an effective salvage therapy that allows for allogeneic hematopoietic stem cell transplantation (HSCT) in remission in patients with advanced acute lymphoblastic leukemia (ALL). Blood 2011;118(Suppl. 1): Abstract 3102.
77. Lock RB, Carol H, Szymanska B, et al. The anti-CD19 antibodydrug conjugate SAR3419 prevents hematolymphoid relapse post induction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Mol Cancer Ther 2011;10(Suppl.): Abstract C107.
78. Schult C, Dahlhaus M, Glass A, et al. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. Anticancer Res 2012;32:463-474.
79. Groth C, Fortini ME. Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin Cell Dev Biol 2012;23:465-472.
80. Messinger Y, Gaynon P, Sposto R, et al. Bortezomib combined with VXLD chemotherapy is highly effective in advanced B-lineage acute lymphoblastic leukemia allowing early study termination due to efficacy. A Therapeutic Advances in Childhood Leukemia (TACL) consortium phase II study. Blood 2011;118(Suppl. 1): Abstract 251 .
81. Garcia-Manero G, Thomas D, Rytting M, et al. A phase 1 study of dose-dense 5-aza-20-deoxycitidine (decitabine) in relapsed refractory acute lymphocytic leukemia (ALL). Blood 2009;114(Suppl. 1): Abstract 2030.
82. Mummery A, Narendran A, Lee KY. Targeting epigenetics through histone deacetylase inhibitors in acute lymphoblastic leukemia. Curr Cancer Drug Targets 2011;11:882-893.
83. Barba P, Sampol A, Calbacho M, et al. Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience. Am J Hematol 2012;87:631-634.